Single stranded DNA aptamers binding NF-κB/RelA
DNA aptamers are high affinity ligands selected by genetic enrichment techniques to bind to specific protein targets. Because these represent chemically stable and reproducible molecules, they have application as affinity reagents and/or therapeutic drugs to affect the target protein's actions. NF-kB is an important mediator of the innate immune response and mediator of tissue inflammation. Although RNA and double stranded DNA aptamers have been identified to bind to the NF-kB family of proteins, the present invention represents the first identification of single stranded DNA aptamers that recognize NFkB RelA. The aptamers disclosed herein bind to several distinct regions of RelA and may be useful to antagonize the DNA binding of RelA as an inhibitor of cellular inflammation, visualize the location or amount of RelA in tissues from pathological conditions, or to quantitatively measure the activated state of RelA by affinity binding.
1. A composition comprising:
an isolated single-stranded oligonucleotide for binding to an activated Nuclear Factor-κB (NF-κB)/RelA complex, wherein the oligonucleotide comprises SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, or the binding-specific variable regions thereof.
2. The composition of claim 1 , wherein the oligonucleotide comprises SEQ ID NO: 21.
3. A testing kit for quantification of a level of activated RelA in a sample comprising:
a first vial comprising an isolated single-stranded oligonucleotide that binds specifically to a RelA comprising the aptamers of SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, or the binding-specific variable regions thereof;
a second optional vial comprising reagents to detect the binding of the oligonucleotide and RelA; and
an instruction booklet comprising step-by-step directions for the usage of the kit.
4. The testing kit of claim 3 , wherein the single-stranded oligonucleotide is immobilized onto beads, suspended in a liquid medium, or immobilized on a probe.
5. The testing kit of claim 3 , wherein the sample is a cellular extract, a growth medium, a body fluid or any combinations thereof.
6. The testing kit of claim 3 , wherein the single-stranded oligonucleotide comprises the binding-specific variable regions of SEQ ID NO: 9.
7. The testing kit of claim 3 , wherein the reagents are adapted for in vivo imaging.
8. The testing kit of claim 3 , wherein the single-stranded oligonucleotide may be conjugated to one or more effectors, wherein the effectors are selected from the group consisting of radionuclides, gold, magnetic nanoparticles, fluorescent labels, quantum dots, and gadolinium.
9. A single-stranded oligonucleotide for binding to an activated Nuclear Factor-κB (NF-κB)/RelA complex, wherein the single-stranded oligonucleotide is selected from the group consisting of SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, or binding-specific variable regions thereof.
10. A composition comprising: a single-stranded oligonucleotide aptamer comprising at least 97%, 94% or 91% homology to at least one of SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, or the binding-specific variable regions thereof, wherein the aptamer binds an activated Nuclear Factor-κB (NF-κB)/RelA complex.
11. The composition of claim 10 , wherein the single-stranded oligonucleotide aptamer consists of at least one of SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, or binding-specific variable regions thereof.
12. The composition of claim 10 , wherein the single-stranded oligonucleotide aptamer consists of SEQ ID NO: 21.